Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.59 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 3/20 | 0.52 |
| ▸ | KIT | P10721 | 3/20 | 0.52 |
| ▸ | FLT3 | P36888 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RAF1 | P04049 | 2/20 | 0.50 |
| ▸ | RET | P07949 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | PLK4 | O00444 | 1/20 | 0.50 |
| ▸ | CIT | O14578 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | MUSK | O15146 | 1/20 | 0.50 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MLNR | O43193 | 1/20 | 0.50 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495737 | 0.88 | CCR2 (0.54) | KDRGRM4BRAFMEN1KMT2A | |
| SCHEMBL6181468 | 0.87 | SMN1; SMN2 (0.50) | BRAFMEN1KMT2AMAPK1HTT | |
| SCHEMBL15689070 | 0.87 | KDR (0.62) | KDRGRM4BRAFKITFLT3 | |
| SCHEMBL5489330 | 0.86 | CCR2 (0.58) | GRM4MEN1KMT2ACA9MAOA | |
| SCHEMBL29590126 | 0.84 | KDR (0.58) | KDRGRM4BRAFMEN1KMT2A | |
| SCHEMBL14783586 | 0.84 | KDR (0.58) | KDRGRM4BRAFMEN1KMT2A | |
| SCHEMBL5492280 | 0.83 | SMN1; SMN2 (0.52) | BRAFMEN1KMT2AMAPK1HTT | |
| SCHEMBL27509542 | 0.82 | SMN1; SMN2 (0.58) | BRAFMEN1KMT2AMAPK1EPHX2 | |
| SCHEMBL15689332 | 0.82 | SMN1; SMN2 (0.58) | KDRGRM4BRAFMEN1KMT2A | |
| SCHEMBL14783435 | 0.82 | KDR (0.56) | KDRGRM4BRAFKITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297696-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2007-11-20 | — | — | US | claimed |
| CN-1259315-C | Antagonists of MCP-1 function and methods of use thereof | TELIK INC (US) | 2006-06-14 | — | — | CN | claimed |
| EP-1363897-B1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK INC (US) | 2005-12-21 | — | — | EP | claimed |
| US-20050054668-A1 | Antagonists of MCP-1 function and methods of use thereof | LABORDE EDGARDO (US) | 2005-03-10 | — | — | US | claimed |
| CN-1494539-A | Antagonists of MCP-1 function and methods of use thereof | ̩ | 2004-05-05 | — | — | CN | claimed |
| EP-1363897-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030105085-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-06-05 | — | — | US | claimed |
| WO-2002070509-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-09-12 | — | — | WO | claimed |
| US-7297696-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2007-11-20 | — | — | US | disclosed |
| CN-1259315-C | Antagonists of MCP-1 function and methods of use thereof | TELIK INC (US) | 2006-06-14 | — | — | CN | disclosed |
| US-20050054668-A1 | Antagonists of MCP-1 function and methods of use thereof | LABORDE EDGARDO (US) | 2005-03-10 | — | — | US | disclosed |
| US-6809113-B2 | FOR THERAPY OF ARTHRITIS, ASTHMA, ATHEROSCLEROSIS, DIABETIC NEPHROPATHY, INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, MULTIPLE SCLEROSIS, NEPHRITIS, PANCREATITIS, PULMONARY FIBROSIS, PSORIASIS, RESTENOSIS TRANSPLANT REJECTION | TELIK, INC. | 2004-10-26 | — | — | US | disclosed |
| CN-1494539-A | Antagonists of MCP-1 function and methods of use thereof | ̩ | 2004-05-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105085-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | KDR 990/4885GRM4 2275/4885BRAF 1333/4885 |
| US-20050054668-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | KDR 1085/4885GRM4 2490/4885BRAF 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.